share_log

Nikola | 424B3: Prospectus

SEC announcement ·  Mar 1 16:43
Summary by Moomoo AI
Nikola Corporation, listed on the Nasdaq Global Select Market under the symbol 'NKLA', filed a prospectus supplement on March 1, 2024, to update and supplement information in its previous prospectus dated July 27, 2020. The supplement includes Amendment No. 1 to the Quarterly Report filed with the SEC on the same date. This filing pertains to the offer and sale of up to 249,843,711 shares of common stock by selling securityholders. The shares are being registered for resale based on registration rights under an agreement between Nikola and the stockholders, which also imposes certain transfer and lock-up restrictions. The update includes information about Rule 10b5-1 trading arrangements adopted by certain officers of Nikola Corporation during the quarter ended September 30, 2023. The closing price of Nikola's common stock on February 29, 2024, was $0.7442. The prospectus supplement and the original prospectus must be read in conjunction, with the supplement taking precedence in case of any inconsistencies.
Nikola Corporation, listed on the Nasdaq Global Select Market under the symbol 'NKLA', filed a prospectus supplement on March 1, 2024, to update and supplement information in its previous prospectus dated July 27, 2020. The supplement includes Amendment No. 1 to the Quarterly Report filed with the SEC on the same date. This filing pertains to the offer and sale of up to 249,843,711 shares of common stock by selling securityholders. The shares are being registered for resale based on registration rights under an agreement between Nikola and the stockholders, which also imposes certain transfer and lock-up restrictions. The update includes information about Rule 10b5-1 trading arrangements adopted by certain officers of Nikola Corporation during the quarter ended September 30, 2023. The closing price of Nikola's common stock on February 29, 2024, was $0.7442. The prospectus supplement and the original prospectus must be read in conjunction, with the supplement taking precedence in case of any inconsistencies.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more